Business Wire

VACCINES-EUROPE

Share
Call to Boost Collaborative Efforts to Save Lives by Reaching Seasonal Influenza Vaccination Targets Across the EU (Vaccines Europe)

At an event held in the European Parliament today, policymakers noted the lack of progress made by EU Member States towards the EU’s 75% target for seasonal influenza vaccination coverage rates among older-age and at-risk groupsi , first adopted in the EU Council Recommendation on seasonal influenza vaccination in 2009.ii

Speakers from the European Commission, European Parliament, European Centre for Disease Prevention and Control (ECDC) and World Health Organisation (WHO) all agreed on the need to seize the opportunity presented by the 10-year milestone of the 2009 Recommendation to renew efforts to boost coverage rates and address the major public health challenges associated with seasonal influenza.

Building on a new study on public perceptions of seasonal influenza disease and vaccination in four EU countriesiii and leveraging some national best practices, panellists stressed the need for all influenza stakeholders to gather in simultaneously addressing influenza vaccine confidence, convenience and complacency issues.

Potential solutions were discussed and identified, which would help addressing specific challenges and make progress towards the ten-year-old 75% seasonal influenza vaccination target, such as:

  • Voluntary exchange of best practices between EU countries on how to increase seasonal influenza vaccination rates. This could be done as part of the EU State of Health initiative cycle.iv Following the publication of Country Health Profiles 2019, the European Commission could establish voluntary exchanges between EU countries, in particular focusing on seasonal influenza vaccination policies and programmesv .
  • EU guidance on data collection for seasonal influenza vaccine coverage rates. This should cover what should be collected, when and how . Currently, data is collected differently and at different times in various EU Member States, which creates an uneven and patchy picture across the EU. An EU Guidance on data collection will allow to monitor whether the EU’s 75% target has been met in all at risk or targeted groups as well as propose appropriate measures to achieve it.
  • Measures to allow all competent healthcare professionals to provide vaccination in convenient locations. For example, by allowing vaccine administration in locations such as workplaces, community pharmacies and schools. Evidence shows that in countries where pharmacists can administer vaccines, the number of people vaccinated increases.vi The EU has a role to play in sharing best practices and providing guidance, and EU Member States will need to introduce appropriate legislations and policies to implement these practices.
  • Further work by EU Member States, as well as the EU and WHO, needs to improve knowledge/education of and confidence in, vaccines among both citizens and healthcare professionals. In some countries, as many as 36.4% of GPs do not believe that the seasonal influenza vaccination is important, and elsewhere the percentage of the general public who believe that it is important is as low as 40.4%. Countries such as Spain and Portugal showcase best practices, with public confidence rates of almost 80%.vii
  • All influenza actors should join forces in, for example, a multi-stakeholder coalitionviii , and launch an European Influenza Awareness Day , that would help to boost influenza vaccination confidence.

MEP Dolors Montserrat (EPP, ES), co-host of the event and former Spanish Health Minister, said that “to progress towards a broader vaccination coverage, especially for people with chronic diseases, we need to:

  1. Raise awareness among healthcare professionals, and policy makers on the problem to build trust in institutions and providers of vaccines;
  2. Empower patients to be correctly informed and participate in the decision making process on the adequate and most cost-effective therapies for their health;
  3. Fight the fake news and the misinformation campaigns through promoting sources of reliable information about vaccination, exposure to positive media messages.”

“The EU has given vaccination a lot of political attention recently – not least through the 2018 Council Recommendation on Strengthened Cooperation Against Vaccine-Preventable Diseases, the EU Joint Action on Vaccination, and the 2019 Global Vaccination Summit. But dwindling seasonal influenza vaccination coverage rates show that much more needs to be done – both at EU and national level” said Magdalena R. de Azero, Executive Director of Vaccines Europe, which organised the event. Ms de Azero concluded: “This event underlines the need for institutions, governments, healthcare professionals and industry to work together to address this challenge.”

Notes

Seasonal influenza poses a significant but often under-recognised challenge to EU health systems. Compared to other infectious diseases, it has the highest impact in terms of mortality and incidence and is estimated to cause up to 70,000 deaths in the EU each year, particularly among older age groups.ixx Its impact is particularly acute among the elderly and other at-risk groups.

Latest EU data (2017, published in 2019) shows that no EU Member State has reached the 75% target for coverage rates. In fact, many countries have seen rates decline, some going as low as single digits (Latvia 6.9%, Estonia 4.8%). The best-in-class EU country, the UK, has seen rates consistently around 70% in recent years (currently 72.6%).xi

About Vaccines Europe

Formed in 1991, Vaccines Europe is a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that represents major innovative research-based vaccine companies as well as small and medium-sized enterprises operating in Europe which account for a large share of human vaccines used worldwide.

i As defined by ECDC. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/risk-groups
ii https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF
iii Full study to be published in the near future. Presented by Professor Frederic Bouder of the University of Stavanger.
iv https://ec.europa.eu/health/state/summary_en
v https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_services_en.pdf .
vi https://www.vaccinestoday.eu/stories/does-pharmacy-vaccination-increase-overall-uptake/
vii https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf
viii For example: https://www.immunize.org/
ix https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.16.17-00454
x https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
xi https://ec.europa.eu/eurostat/web/products-eurostat-news/product/-/asset_publisher/VWJkHuaYvLIN/content/DDN-20191209-2

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Blind Sailor Takes the Stage at WEF: "HIRO’s CHOICE" Project to Set Sail13.1.2026 05:00:00 CET | Press release

A Solo, Non-Stop Crossing of the Pacific Ocean “Blind Sailor Single-Handed Pacific Crossing Project 2027” is a world-first initiative in which Mitsuhiro Iwamoto, a completely blind Japanese yachtsman (blind sailor) based in San Diego, will attempt a solo, non-stop trans-Pacific crossing in the spring of 2027. Sailing a 28-foot yacht single-handedly, he aims to cross the Pacific Ocean from San Diego on the U.S. West Coast to Amakusa, Kumamoto Prefecture, Japan, without making port. Iwamoto will speak about this project at the World Economic Forum Annual Meeting 2026, to be held in January 2026. Project URL: https://hiros-choice.com/ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108087321/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific The message he most wishes to convey at the WEF is the power of choice. He lost his sight at the age of sixteen—a moment when he nearly gave up on

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye